Upon joining the study, an initial assessment will be conducted to confirm eligibility. This includes verifying that there is at least one measurable lesion and assessing overall health status.

A performance status evaluation will be conducted to ensure the ability to perform daily activities is either fully active or restricted in physically strenuous activity but ambulatory.

The treatment phase begins with the administration of pembrolizumab through an intravenous infusion. This involves receiving the medication directly into the bloodstream through a vein.

Following this, osimertinib mesylate will be taken orally. The specific dosage and frequency will be determined by the study team based on individual needs and responses.

In addition to the initial medications, BL-B01D1 will be administered intravenously. This is part of the combination therapy to evaluate its safety and effectiveness.

The combination of these treatments aims to determine the maximum safe dose and to observe any potential side effects or adverse reactions.

Throughout the trial, regular monitoring will occur to track the body’s response to the treatment. This includes blood tests, imaging studies, and other necessary evaluations.

The primary focus is to identify any adverse events, which are unexpected medical problems that occur during treatment, and to ensure the safety of the participant.

After completing the treatment phase, follow-up visits will be scheduled to continue monitoring health status and any long-term effects of the treatment.

These visits are crucial for assessing the duration of response to the treatment and overall outcomes.